• “National Health Industry International Innovation Park" established


	• “Shanghai Jiao Tong University----Triplex International Biosciences Joint Research and Development Center for Precision Medicine”

	• “Fujian Province Science and Technology Giant Leading Enterprise”


	• “Xiamen Science and Technology Giant Enterprise 2016” 


	• Cooperate with MGmed (South Korea) to develop the chromosome defect diagnosis market

	• Joint laboratory established in Cooperation with Beijing Obstetrics and Gynecology Hospital, Capital Medical University


	• "Joint Key Laboratory of Transformation Medicine" established with Institute of Biophysics, Chinese Academy of Sciences


	• Became the director unit of Xiamen Medical Device Association

	• Officially relocated to Triplex Biological Park (Xiamen) 


	• Selected as "Leading Industrial Enterprise" in Fujian Province in 2014


	• Selected as "Key Industrial Enterprises" in Xiamen City in 2014


	• Approved as "Xiamen Intellectual Property Enterprise"


	• "Xiamen Innovative Enterprise" awarded


	• "High-tech Enterprise of Xiamen 2014" awarded

	• "Key Industrial Enterprises in Xiamen of 2013" awarded 


	• General agent of DIAPATH S.P.A Italy in China. 


	• “The Fujian Provincial Key Laboratory of Joint Hepatobiliary Technology Innovation” established cooperatively with Shanghai Oriental Hepatic Hospital of Second Military Medical University headed by academician Wu Mengchao and Meng Chao Hepatobiliary Hospital of Fujian Medical University.  

	• Complete the first phase of Xiamen Biologic Park facilities


	• Cooperate with Hitachi to develop Chinese molecular diagnostic market
	

		• "In Vitro Diagnosis Technology Enterprise Science and Technology Innovation Platform of Fujian"
	
	

		• Beijing Taipu Shunkang Medical Laboratory Co., Ltd. and Fuzhou Taikang Puzhong General Outpatient Department Co., Ltd officially operated
	



	

	• Beijing Taipu Shunkang Medical Laboratory Co., Ltd. Established


	• "Xiamen's Most Growing Small and Medium Enterprises" awarded


	• Fuzhou Taikang Puzhong Comprehensive Outpatient Department and Clinical Examination Center Established


	• Approved to establish "Fujian Academician Expert Workstation" and "Fuzhou Academician Expert Workstation"


	• Selected as "Fujian-Taiwan Medical Device Science and Technology Cooperation Base" by Fujian provincial government


	• Approved by the National Development and Reform Commission to establish the National and Local Joint Engineering Laboratory for Molecular Diagnostic.


	


	

	• "High-tech Enterprise of Fuzhou" awarded


	• Fujian Triplex Bioscience Co., Ltd. was renamed "Triplex Bioscience (China) Co., Ltd."


	• "Taipu-Fuzhou University Medical Device Research and Development Center" established

• Signed the strategic cooperation and exclusive distribution agreement with MedMira, a leading international developer of rapid diagnostic products.

	• "High-tech Enterprise" awarded


	• Start the construction of the first phase of Xiamen base


	• Establishment of Research and Development Center in Beijing Zhongguancun Life Science Park


	• Cooperate with Beijing Tuberculosis Research Institute to develop a rapid diagnostic kit for Mycobacterium tuberculosis.


	• Approved by Fujian Development and Reform Commission to establish Fujian Molecular Diagnostic Technology Engineering Laboratory


	• Cooperate with Xi 'an Jiaotong University to set up TIB-Xi 'an Jiaotong University Biomedical Analysis Technology and Instrument Research and Development Center


	



	

• Cooperate with Peking University Health Science Center to establish TIB-Peking University Laboratory of Medical Molecular Pathology

• Fuzhou Triplex Biological Science Co., Ltd established

• 15 molecular diagnostic reagents successfully developed

• Fujian Triplex Bioscience Co., Ltd was established and later renamed "Triplex Bioscience (China) Co., Ltd."  Main products of FISH, LBC and PCR were introduced into the market.


	 

• In cooperation with Peking University Health Science Center to successfully develop a rapid diagnostic kit of  fluorescence quantitative PCR  for SARS virus was developed and distributed free of charge to medical units across the country.

	• Establishment of Triplex International Bioscience (Hong Kong) Co., Ltd.


	• Cooperate with Peking University Health Science Center to investigate the market of clinical molecular diagnostic products and introduce the US molecular diagnostic technologies.